Diabetic Macular Edema – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of DME for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s DME forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with DME?
Of all people with DME, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with DME, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DME over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following DME subpopulations:
Diagnosis status.
Treatment status.
Note: Coverage may vary by country and region.
Source: Clarivate

launch Related Market Assessment Reports